Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Washington University School of Medicine
University Hospital, Limoges
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Pfizer
Kelonia Therapeutics, Inc.
Quetzal Therapeutics
Medical College of Wisconsin
Orca Biosystems, Inc.
Taiho Oncology, Inc.
Celgene
University of Southern California
Assistance Publique - Hôpitaux de Paris
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Takeda
Thomas Jefferson University
Medical College of Wisconsin
Cogent Biosciences, Inc.
Eli Lilly and Company
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Kedrion S.p.A.
Ossium Health, Inc.
Memorial Sloan Kettering Cancer Center
Center for International Blood and Marrow Transplant Research
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Medical College of Wisconsin
University of Michigan Rogel Cancer Center
Nantes University Hospital
Brigham and Women's Hospital
Herlev and Gentofte Hospital
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Pfizer
Fred Hutchinson Cancer Center
The First Affiliated Hospital of Guangzhou Medical University
Stanford University
Zhejiang University
Rigshospitalet, Denmark
University of Colorado, Denver
Fujian Medical University
Massachusetts General Hospital
Constellation Pharmaceuticals